Cargando…
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years
Since authorization of the Pfizer-BioNTech COVID-19 Vaccine, mRNA (Comirnaty), real-world evidence has indicated the vaccines are effective in preventing COVID-19 cases and related hospitalizations and deaths. However, increased cases of myocarditis/pericarditis have been reported in the United Stat...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958165/ https://www.ncbi.nlm.nih.gov/pubmed/35370016 http://dx.doi.org/10.1016/j.vaccine.2022.03.030 |